FDA Targets Experimental Multiple Sclerosis Treatment
The U.S. Food and Drug Administration on Thursday warned doctors and people suffering from multiple sclerosis and chronic cerebrospinal venous insufficiency about an experimental treatment called "liberation therapy" or "the liberation...To view the full article, register now.
Already a subscriber? Click here to view full article